<DOC>
	<DOCNO>NCT01251978</DOCNO>
	<brief_summary>Ranibizumab proven benefit improve perfusion retina patient Choroidal Melanoma . The investigator consider high dos Ranibizumab help reduce number laser treatment might need control tumor .</brief_summary>
	<brief_title>Ranibizumab Adjuvant Therapy Treatment Choroidal Melanoma ( Cohort 2 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>18 year old Primary pigment amelanotic choroidal melanoma measure 16 mm less large basal diameter 6 mm less apical height . Location tumor , posterior equator eye . Documented growth tumor AB scan . Ability provide write informed consent comply study assessment full duration study . Pregnancy lactation . Premenopausal woman use adequate contraception . Current infection inflammation either eye . Extension tumor orbit . Regional spread metastatic disease . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Any known allergy component use study . Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Choroidal melanoma</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Transpupillary Thermotherapy</keyword>
	<keyword>CSTIP</keyword>
	<keyword>Indocyanine Green</keyword>
</DOC>